Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs Vanguard International High Dividend Yield ETF (VYMI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spyre Therapeutics Inc. Common Stock vs Vanguard International High Dividend Yield ETF — how do they compare? Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B), while Vanguard International High Dividend Yield ETF trades at $100.51 (market cap $22.80B). The key difference: Vanguard International High Dividend Yield ETF is far larger — about 3× Spyre Therapeutics Inc. Common Stock's market cap, and Vanguard International High Dividend Yield ETF is more actively traded (740,346 versus 1,441,031). Which is the better fit depends on your goals — on Pluang, investors hold Spyre Therapeutics Inc. Common Stock for 0 Days and Vanguard International High Dividend Yield ETF for 51 Days on average.
| SYRE | VYMI | |
|---|---|---|
Market Cap | $7.52B | $22.80B |
Volume | 1,441,031 | 740,346 |
Sector | Health | Broad Market / Factor |
52-Week High | $108.92 | $107.13 |
52-Week Low | $22.18 | $84.45 |
Typical Hold Time | 0 Days | 51 Days |
Enterprise Value | $6.52B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
VYMI trades at $101.52, up 0.71% with a bearish technical signal from moving averages. The ETF shows strong institutional interest with Envestnet increasing holdings by 22% in Q2 2026. Recent news highlights VYMI's 29% one-year return and 3.61% dividend yield, outperforming peers with a 5-year average annual return of 14.13% according to Seeking Alpha on September 21, 2026.
The outlook remains positive with sector catalysts in financials, energy, and healthcare supporting dividend growth. Key risks include global market volatility and currency exposure. Analyst sentiment leans bullish with VYMI positioned as an attractive international dividend play amid rising global rates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →About Vanguard International High Dividend Yield ETF
VYMI is an index-based ETF that provides exposure to non-U.S. companies across developed and emerging markets that are characterized by high dividend yields. It tracks the FTSE All-World ex US High Dividend Yield Index, offering a diversified, low-cost way to capture international income while serving as a tactical hedge against U.S. market concentration.
Read more on VYMI →
